VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease
Synopsis
The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) rose as much as 7% after hours on Monday after the company announced positive 36-week data from its ongoing late-stage trial evaluating povetacicept in immunoglobulin A nephropathy.
IgA nephropathy or Berger’s disease is an autoimmune kidney disease occurring when immunoglobulin A (IgA) antibody clumps deposit in the kidney’s glomeruli, causing inflammation and damage.
The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal. The reduction was consistent across subgroups, the company said.
Patients treated with povetacicept also demonstrated a 77.4% reduction from baseline in serum galactose deficient IgA1, the company added. Serum galactose-deficient IgA1 (Gd-IgA1) is a critical, disease-specific biomarker for IgA nephropathy.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.